Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidemiology of brain metastases.
Nayak L, Lee EQ, Wen PY. Nayak L, et al. Curr Oncol Rep. 2012 Feb;14(1):48-54. doi: 10.1007/s11912-011-0203-y. Curr Oncol Rep. 2012. PMID: 22012633
Novel Therapies for Primary Central Nervous System Lymphomas.
Aquilanti E, Herrity E, Nayak L. Aquilanti E, et al. Among authors: nayak l. Curr Neurol Neurosci Rep. 2024 Dec;24(12):621-629. doi: 10.1007/s11910-024-01376-5. Epub 2024 Oct 11. Curr Neurol Neurosci Rep. 2024. PMID: 39390309 Review.
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma.
Iwamoto FM, Tanguturi SK, Nayak L, Wang TJ, Desai A, Lustig RA, Bagley S, Wong ET, Hertan LM, McCluskey C, Hayden J, Muzikansky A, Nakhawa S, Japo J, Bossi CC, Meylan M, Tian Y, Barlow GL, Speliakos P, Ayoub G, Meredith DM, Ligon KL, Haas-Kogan D, Huang K, Wucherpfennig KW, Wen PY, Reardon DA. Iwamoto FM, et al. Among authors: nayak l. Clin Cancer Res. 2025 Jan 17;31(2):316-327. doi: 10.1158/1078-0432.CCR-24-1629. Clin Cancer Res. 2025. PMID: 39513953 Clinical Trial.
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Lee EQ, Muzikansky A, Duda DG, Gaffey S, Dietrich J, Nayak L, Chukwueke UN, Beroukhim R, Doherty L, Laub CK, LaFrankie D, Fontana B, Stefanik J, Ruland S, Caruso V, Bruno J, Ligon K, Reardon DA, Wen PY. Lee EQ, et al. Among authors: nayak l. Cancer Med. 2019 Oct;8(13):5988-5994. doi: 10.1002/cam4.2505. Epub 2019 Aug 24. Cancer Med. 2019. PMID: 31444999 Free PMC article. Clinical Trial.
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma.
Lim-Fat MJ, Iorgulescu JB, Rahman R, Bhave V, Muzikansky A, Woodward E, Whorral S, Allen M, Touat M, Li X, Xy G, Patel J, Gerstner ER, Kalpathy-Cramer J, Youssef G, Chukwueke U, McFaline-Figueroa JR, Nayak L, Lee EQ, Reardon DA, Beroukhim R, Huang RY, Bi WL, Ligon KL, Wen PY. Lim-Fat MJ, et al. Among authors: nayak l. Clin Cancer Res. 2024 Apr 1;30(7):1327-1337. doi: 10.1158/1078-0432.CCR-23-3018. Clin Cancer Res. 2024. PMID: 38252427
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression.
Deng D, Hammoudeh L, Youssef G, Chen YH, Shin KY, Lim-Fat MJ, McFaline-Figueroa JR, Chukwueke UN, Tanguturi S, Reardon DA, Lee EQ, Nayak L, Bi WL, Arnaout O, Ligon KL, Wen PY, Rahman R. Deng D, et al. Among authors: nayak l. Neurooncol Adv. 2023 Jul 8;5(1):vdad083. doi: 10.1093/noajnl/vdad083. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37554224 Free PMC article.
321 results